Unknown

Dataset Information

0

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.


ABSTRACT: The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide. These agents have been shown to reduce A1C (by ?0.8-1.6%), body weight (by ?1-3 kg), blood pressure, and lipids. GLP-1 receptor agonists are associated with a low risk of hypoglycemia, and the most common adverse effects are gastrointestinal. Proper patient selection and education can assist in achieving positive treatment outcomes.

SUBMITTER: Hinnen D 

PROVIDER: S-EPMC5556578 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.

Hinnen Deborah D  

Diabetes spectrum : a publication of the American Diabetes Association 20170801 3


The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type  ...[more]

Similar Datasets

| S-EPMC8017582 | biostudies-literature
| S-EPMC10258616 | biostudies-literature
| S-EPMC7136364 | biostudies-literature
| S-EPMC5357070 | biostudies-other
| S-EPMC4321868 | biostudies-literature
| S-EPMC10797415 | biostudies-literature
| S-EPMC8169368 | biostudies-literature
| S-EPMC7366314 | biostudies-literature
| S-EPMC7744318 | biostudies-literature
| S-EPMC8063104 | biostudies-literature